Pfizer (PFE)
(Delayed Data from NYSE)
$28.93 USD
-0.29 (-0.99%)
Updated Oct 21, 2024 04:00 PM ET
After-Market: $28.99 +0.06 (0.21%) 4:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$28.93 USD
-0.29 (-0.99%)
Updated Oct 21, 2024 04:00 PM ET
After-Market: $28.99 +0.06 (0.21%) 4:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
Lilly to Acquire Private Biotech for Boosting Pain Portfolio
by Zacks Equity Research
Lilly (LLY) inks a deal to acquire Disarm Therapeutics for an upfront payment of $135 million to strengthen its pain and neurological diseases portfolio.
Retail and Core Retail Sales Jump in September
by Zacks Equity Research
Retail and Core Retail Sales Jump in September.
Retail Sales +1.9%, Industrial Production -0.6%
by Mark Vickery
While September Retail Sales were ahead of expectations, Industrial Production last month was decidedly not.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Pfizer, Target, Prudential Financial and Seagate Technology
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Pfizer, Target, Prudential Financial and Seagate Technology
Merck's Keytruda Gets FDA Nod for Expanded Use in Lymphoma
by Zacks Equity Research
The FDA approves Merck's (MRK) Keytruda for the treatment of adult patients with relapsed or refractory cHL who progress after frontline therapy.
Pharma Stock Roundup: J&J's Q3 Earnings, Pause on Coronavirus Studies & Other Updates
by Kinjel Shah
J&J (JNJ) beats Q3 estimates for earnings and sales. J&J and Lilly (LLY) pause studies on their coronavirus vaccine and antibody candidates, respectively.
Moderna Gets Consent to File MAA for Coronavirus Vaccine in EU
by Zacks Equity Research
Moderna (MRNA) gets permission from the European Medicines Agency to submit a marketing authorization application for mRNA-1273, its vaccine candidate against COVID-19.
Top Analyst Reports for Johnson & Johnson, Pfizer & Target
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including JNJ, PFE and TGT.
J&J (JNJ) Beats on Q3 Earnings & Sales, Ups 2020 Guidance
by Zacks Equity Research
J&J (JNJ) beats third-quarter 2020 estimates for both earnings and sales. It increases its adjusted earnings and sales outlook for 2020.
J&J's Coronavirus Vaccine Studies Paused Post Adverse Event
by Zacks Equity Research
J&J's (JNJ) large phase III ENSEMBLE study on its coronavirus vaccine candidate, JNJ-78436735, is expected to enroll 60,000 adult participants and compares a single dose of the vaccine to placebo.
Pfizer (PFE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $36.82, marking a +0.08% move from the previous day.
Pfizer's (PFE) Ibrance Fails in Early Breast Cancer Study
by Zacks Equity Research
Pfizer's (PFE) Ibrance is marketed for the treatment of HR+, HER2- advanced or metastatic breast cancer but not for any early breast cancer indication.
Pharma Stock Roundup: LLY, AZN, PFE, GSK Progress on Coronavirus Programs
by Kinjel Shah
Lilly (LLY), Pfizer (PFE) and AstraZeneca (AZN) provide updates on their coronavirus vaccine/treatment programs.
Here's Why Small-Cap ETFs Are Hitting New Highs
by Sweta Killa
Small-Cap ETFs hit new highs in the recent trading session. We have highlighted some solid reasons for their strong performance.
Pfizer, BioNTech Begin EU Rolling Filing of Coronavirus Vaccine
by Zacks Equity Research
Pfizer (PFE) and partner BioNTech start rolling review of their coronavirus vaccine candidate, BNT162b2, in Europe.
SpringWorks Inks Deal With Pfizer for Nirogacestat Combo
by Zacks Equity Research
SpringWorks (SWTX) inks a collaboration deal with Pfizer to evaluate nirogacestat along with the latter's BCMA-targeted therapy PF-06863135 for treating relapsed/refractory multiple myeloma. Stock up.
Pfizer (PFE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $36.75, moving +1.02% from the previous trading session.
The Zacks Analyst Blog Highlights: MRNA, AZN, PFE and BNTX
by Zacks Equity Research
The Zacks Analyst Blog Highlights: MRNA, AZN, PFE and BNTX
AstraZeneca Resumes Japan Study on Coronavirus Vaccine Candidate
by Zacks Equity Research
AstraZeneca's (AZN) late-stages studies on its COVID-19 vaccine candidate, AZD1222 in Japan resume. The U.S. study remains on hold.
Moderna Coronavirus Vaccine May Not Be Ready Before US Elections
by Zacks Equity Research
Moderna (MRNA) does not expect to apply for an emergency use authorization for its mRNA-based coronavirus before the U.S. presidential election scheduled on Nov 3.
Pharma Stock Roundup: FDA Approves New Uses of PFE, JNJ & GSK's Drugs
by Kinjel Shah
New indications of Glaxo's (GSK) Nucala J&J's (JNJ) Simponi Aria and Pfizer's (PFE) Xeljanz get FDA's nod.
The Zacks Industry Rank Highlights: Gilead, Pfizer, Moderna, Johnson & Johnson and AstraZeneca
by Zacks Equity Research
The Zacks Industry Rank Highlights: Gilead, Pfizer, Moderna, Johnson & Johnson and AstraZeneca
Zacks Market Edge Highlights: Chevron, Exxon Mobil, BP, Pfizer and Bank of America
by Zacks Equity Research
Zacks Market Edge Highlights: Chevron, Exxon Mobil, BP, Pfizer and Bank of America
Should you Buy Big Dividend Paying Stocks?
by Tracey Ryniec
ExxonMobil has a dividend yielding almost 10%. Is it risky to buy the big dividend payers or is it a golden opportunity?
5 Vaccine Stocks to Buy Now
by John Blank
The COVID-19 sponsor companies are either in the Zacks Large Cap Pharma industry, or in Zacks Biomedical and Genetics industry.